Discuss L-Carnitine on glp1chat
Join the forum to discuss research with other members.
At a glance
L-Carnitine helps carry long-chain fats into mitochondria, where cells can use them for energy. This transport job is well understood; studies of extra L-carnitine ask whether supplying more changes outcomes in a particular setting. It is not a peptide.
Cells make energy from fats inside structures called mitochondria. L-carnitine helps shuttle long-chain fats across the mitochondrial boundary so they can be used there. This transport job explains why it appears in metabolism research. It does not mean adding more automatically burns more fat: studies must ask whether a particular person was deficient and whether the added amount actually changes a meaningful outcome.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Studies vary by route, baseline status and indication. Oral supplementation results cannot automatically justify an injectable research-vial schedule.[1][2][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of L-Carnitine.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 200 mg · 1 source tables
Standard / Gradual Approach (2.0 mL = 100 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 50 mg | 50 units (0.50 mL) |
| Weeks 3–8 | 100 mg | 100 units (1.0 mL) |
| Weeks 9–12 | 100 mg | 100 units (1.0 mL) |
Frequency: Inject once daily subcutaneously. This 2.0 mL reconstitution provides optimal concentration for convenient dosing: 100 mg maintenance dose = exactly 1.0 mL (100 units)[7]. For advanced protocols requiring 150–200 mg daily, doses above 1.0 mL may be split into two injections at different sites to improve comfort.
Additional schedule context & duration
Concise summary of the once-daily subcutaneous regimen.
- Goal: Support mitochondrial fatty acid oxidation and energy metabolism while avoiding TMAO production associated with oral dosing[4].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 50–100 mg daily with gradual titration; advanced protocols may use up to 200 mg daily.
- Reconstitution: 2.0 mL per 200 mg vial (100 mg/mL) for precise 1:1 unit-to-milligram measurement.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw cycles.
Suggested daily titration approach based on clinical literature.
- Start: 50 mg daily for Weeks 1–2 to assess tolerance and monitor for injection-site reactions[7].
- Maintenance: Increase to 100 mg daily from Week 3 onward; this is a reasonable maintenance dose for most research purposes[7].
- Advanced: Up to 200 mg daily for robust experimental protocols, if clearly supported by research findings[7].
- Frequency: Once per day subcutaneously (any consistent time; morning or pre-exercise commonly used).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks with continued monitoring.
- Site Rotation: Rotate injection sites systematically (abdomen, thighs, upper arms) to prevent tissue irritation.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water (0.9% benzyl alcohol) with a sterile syringe.
- Inject slowly down the vial wall to minimize foaming; avoid direct stream onto powder.
- Gently swirl or roll the vial until powder is fully dissolved (do not shake vigorously).
- Label vial with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
- Use within 2–4 weeks; bacteriostatic water preservative inhibits microbial growth during multi-dose use[6].
Storage Instructions
Proper storage preserves peptide stability and potency.
- Lyophilized (unreconstituted): Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure. Keep vial tightly sealed. Stable for months to years when frozen[11].
- Reconstituted solution: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing. Do not freeze reconstituted solution as this can degrade the peptide[7].
- Stability timeline: With bacteriostatic water (0.9% benzyl alcohol), reconstituted L-Carnitine remains usable for 2–4 weeks when refrigerated[7][11]. Benzyl alcohol suppresses bacterial growth during multi-dose use[6].
- Before use: Allow refrigerated vials to reach room temperature before opening to reduce condensation. Inspect solution before each use; discard if discolored or contains precipitates.
- Avoid freeze–thaw cycles: Repeated freezing and thawing degrades peptide integrity; aliquot into smaller vials if long-term storage is needed[11].
Materials & quantity planning
Source materials checklist · 200 mg
Plan based on an 8–16 week daily protocol using 100 mg maintenance dose (most common). If starting with 50 mg titration (Weeks 1–2), subtract ~3–4 vials from totals below.
-
Peptide Vials (L-Carnitine, 200 mg each):
- 8 weeks (56 days @ 100 mg/day) ≈ 28 vials
- 12 weeks (84 days @ 100 mg/day) ≈ 42 vials
- 16 weeks (112 days @ 100 mg/day) ≈ 56 vials
Note: Each 200 mg vial reconstituted at 2.0 mL provides two 100 mg doses (or four 50 mg doses).
-
Insulin Syringes (U-100, 1 mL capacity):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 8 weeks (28 vials): 56 mL → 6 × 10 mL bottles
- 12 weeks (42 vials): 84 mL → 9 × 10 mL bottles
- 16 weeks (56 vials): 112 mL → 12 × 10 mL bottles
-
Alcohol Swabs: One for vial stopper + one for injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
- Sharps Container: For safe disposal of used syringes and needles.
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 200 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Clinical Nutrition ESPEN (2020) — Talenezhad N et al. Meta-analysis of 37 RCTs: L-carnitine supplementation yields ~1.2 kg weight loss at ~2,000 mg/day oral dosing with diminishing returns above that dose (PMID: 32359762) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
American Journal of Kidney Diseases (2001) — Brass EP et al. IV L-carnitine (10–40 mg/kg after dialysis, 3×/week for 24 weeks) increased plasma carnitine, reduced fatigue, preserved exercise capacity in hemodialysis patients with excellent safety profile (PMID: 11325685) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Continue exploring
Related topics are not interchangeable compounds or formulations.